Disc Medicine, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.36M, a 164.13% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.01M, a 75.65% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.53M, a 281.80% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $892.00K, a 57.32% increase year-over-year.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $8.64M, a 190.36% increase from fiscal 2024.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $2.98M, a 7.71% increase from fiscal 2023.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.76M, a 1161.64% increase from fiscal 2022.
- Disc Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $219.00K, a 222.06% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.36M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.01M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $8.64M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.53M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $892.00K 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $575.00K 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $2.98M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $401.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $567.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $806.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.76M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $607.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $242.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $1.07M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $219.00K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $22.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $86.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $55.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $68.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $71.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $106.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $4.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $164.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $3.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $9.00K 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $10.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |